It is a change in the final form: a revised claim, an altered hyperlink, a substituted image, a modified audience setting, or a prescribing-information pathway that no longer matches the certified version.
Under Clause 8.1 of the ABPI Code of Practice, promotional material must not be issued unless its final form has been certified before release. The certifier must be a UK-registered medical practitioner, pharmacist, or, for dental products, dentist. The certifier cannot be the person responsible for developing or drawing up the material.
Digital promotion increases the number of variables inside that requirement. A web page is not only a page. It can include expandable content, embedded video, downloadable documents, QR codes, tracking parameters, and links to content controlled by another system. The medical signatory review therefore has to assess the asset as it will exist in distribution, not as it appears in a static draft.
The certification mandate: ABPI Clause 8.1 and final form
The central control is simple. The certified item must be the item that is issued.
This creates a strict cause-and-effect sequence:
1. The promotional claim is drafted and supported by the approved evidence.
2. Medical, legal, and regulatory functions assess the content.
3. The asset reaches its final form.
4. An eligible medical signatory certifies that final form.
5. The company issues the certified asset without subsequent amendment.
The fifth step is where digital workflows create variance. In print production, a post-certification change is visible. A new paragraph, altered layout, or substituted page can usually be identified through document comparison. In a digital environment, the change may occur in a content-management system after approval. A destination URL can be redirected. A dynamic component can be populated from a separate database. A field can be updated without reopening the entire asset in the review platform.
The compliance question is not limited to whether the principal copy was approved. It concerns the complete promotional communication:
- headline and body claims;
- product name, indication, and presentation;
- safety information;
- references and citation placement;
- images, animation, and audio;
- calls to action;
- forms and response mechanisms;
- downloadable files;
- embedded or linked content;
- QR codes and their destination;
- audience and channel configuration;
- version identifier and release date.
A medical signatory review that excludes one of these components does not represent a review of the final promotional material. It represents a partial review.
The distinction is quantifiable. A content owner can state that the copy was approved. That does not establish that the issued asset was certified. The relevant evidence is the relationship between the approved version, the certificate, and the deployed version.
Certification attaches to the issued form, not to the intention behind the campaign.
Static approval is not digital control
Many review failures originate in a static-document model applied to a digital asset. The asset is converted to a PDF, reviewed, certified, and then reconstructed in a web platform. The deployed page may differ from the reviewed file in layout, interaction, or content hierarchy.
That reconstruction introduces a new control point. The final rendered page must be captured or otherwise preserved in a form that permits later verification. A text document showing the approved wording is insufficient if the live page contains an additional banner, a different claim order, or a linked document that was not included in the certification package.
The review record should identify the asset with enough precision to establish its identity. Typical control fields include:
| Control field | Compliance purpose | Failure if absent |
|---|---|---|
| Asset identifier | Links the material to the review record | Multiple versions become difficult to distinguish |
| Version and approval date | Establishes the certified state | Later amendments may be mistaken for approved content |
| Channel and audience | Defines the distribution context | Professional and public-facing content may be conflated |
| Complete content capture | Preserves the reviewed form | Dynamic or interactive elements may disappear |
| Signatory identity and qualification | Demonstrates eligibility | Certification authority cannot be established |
| Final deployment evidence | Confirms what was issued | Approval may not correspond to live content |
The exact internal record format varies by company. The control objective does not. The company must be able to demonstrate what was reviewed, who certified it, and what was issued.
How the MLR committee changes the review cycle
In the United States, the Promotional Review Committee, commonly called MLR, usually includes Medical, Legal, and Regulatory representatives. The committee assesses promotional content against applicable FDA standards and internal policy. This is a cross-functional review model. It is not interchangeable with the UK medical signatory requirement.
The difference is structural.
In a US workflow, Medical may evaluate scientific accuracy and fair balance. Legal may evaluate liability, substantiation, and language risk. Regulatory may assess consistency with the approved product information and applicable promotional requirements. The final approval may be recorded through a committee workflow, electronic approval, or controlled content system.
Under the ABPI framework, the additional issue is the certification of the final form by an eligible registered professional. The person certifying the material must not be the person responsible for developing or drawing up that material. A committee approval record does not automatically replace that certification requirement.
This distinction matters in global campaigns. A single master asset can contain a common claim platform, regional product information, market-specific safety text, and different distribution mechanisms. Approval in one jurisdiction does not create approval in another. The control must be mapped to the jurisdiction, channel, audience, and final content.
The review cycle and its operational constraint
The research basis identifies an average MLR review cycle of approximately 15 to 45 days, depending on material complexity. This is an operational range, not a regulatory deadline. A simple email module and an interactive product website do not present the same review burden.
Cycle duration expands when:
- the claim requires new evidence assessment;
- the asset contains multiple indications or populations;
- the material uses comparative language;
- the content links to external or dynamic information;
- the prescribing information is region-specific;
- the asset has multiple language versions;
- the review involves late-stage design changes;
- the audience is not clearly defined;
- the same component is reused across several channels.
A compressed launch schedule does not reduce the compliance threshold. It only reduces the available mitigation period. When review is forced into the final days before release, the most common result is not a faster assessment. It is uncontrolled amendment after signatory approval.
A controlled workflow separates content approval from deployment approval:
1. Content review. The claims, references, safety statements, and intended audience are assessed.
2. Production review. The digital build is checked against the approved content.
3. Final-form certification. The eligible signatory reviews the form that will be issued.
4. Release control. The approved version is published without unapproved modification.
5. Post-release surveillance. The company verifies that the live asset remains aligned with the certified record.
The third and fourth stages are frequently collapsed. That is a control defect.
UK and US approaches cannot be merged by terminology
The term “medical signatory review” is often used broadly across pharmaceutical operations. The underlying obligations remain jurisdiction-specific.
| Issue | UK ABPI framework | US MLR framework |
|---|---|---|
| Core control | Certification of final promotional form under Clause 8.1 | Cross-functional review against applicable FDA and company requirements |
| Medical authority | Eligible UK-registered medical practitioner, pharmacist, or relevant dentist | Medical reviewer or designated Medical function representative |
| Independence rule | Certifier must not be the person responsible for developing or drawing up the material | Committee roles and independence are governed by company process and applicable requirements |
| Digital risk | Final form, subsequent amendments, records, and prescribing information pathway | Claim substantiation, fair balance, approved labeling alignment, channel and audience controls |
| Record requirement | Preserve certificates and final certified materials in paper or electronic form | Retain review and approval records under the company’s controlled process |
| Primary failure mode | Issuing an uncertified or amended final form | Releasing content outside approved MLR scope or without adequate support |
This table does not establish that one system is more rigorous than the other. It establishes that the control architecture differs. A global standard operating procedure can harmonise evidence collection. It cannot erase local requirements.
Digital implementation: Clause 12 prescribing information and QR codes
The 2024 ABPI Code permits prescribing information under Clause 12 to be provided through a QR code for printed and certain digital promotional materials. The option changes the delivery mechanism. It does not remove the prescribing-information obligation.
A QR code is therefore a regulated pathway to required information, not a design accessory. The medical signatory review has to cover both the code and its destination.
The relevant control sequence is:
1. The QR code is generated for the approved destination.
2. The destination contains the required prescribing information in the permitted form.
3. The code is embedded in the final promotional asset.
4. The code is scanned from the actual issued format.
5. The destination is verified for content, accessibility, and alignment.
6. The code, destination, and verification record are retained with the certified asset.
A code that resolves successfully can still create a compliance defect. It may point to an outdated document. It may open a page containing additional promotional claims. It may require an authentication step unavailable to the intended audience. It may function in the test environment but fail after migration to the production environment. It may redirect to a destination whose content can be altered without reopening the approved promotional asset.
The risk is not restricted to technical failure. Destination content is part of the communication pathway. The control must establish which content was available through the code at the time of certification and whether that content remained within the approved scope at the time of issue.
Dynamic content requires a defined boundary
Digital materials often include components that are not fixed at the time of page load. Examples include a product locator, a content feed, a dosage calculator, a consent module, or a region-based information panel. Each component creates a question of scope.
If the component can change the clinical meaning of the communication, it belongs inside the review boundary. If it can display promotional or product information, it requires version control and ownership. If it can link to material outside the certified asset, the link destination must be assessed according to the applicable policy and jurisdiction.
The review file should distinguish between:
- fixed promotional copy;
- fixed mandatory information;
- interactive functionality;
- linked material;
- system-generated content;
- user-submitted content;
- content controlled by an external vendor.
The last category is frequently underestimated. Outsourcing hosting or development does not outsource regulatory accountability. A vendor can operate the platform. The pharmaceutical company remains responsible for the material it issues under its name.
The QR code is not the record
A QR code image alone does not demonstrate what it resolved to. The record should preserve the destination and the verification state. Where the destination is hosted on a platform capable of later amendment, the company should apply a controlled publication process and retain evidence of the approved content.
The record does not require a universal format. It requires reconstructability. An auditor should be able to determine:
- which promotional asset contained the code;
- which destination was intended;
- what information the destination displayed at certification;
- who verified the pathway;
- when the verification occurred;
- whether later changes triggered re-review.
Without that chain, the company can show a code. It cannot show controlled delivery of prescribing information.
Separation of duties and signatory independence
Clause 8.1 contains a direct separation-of-duties requirement. The person certifying the promotional material must not be the person responsible for developing or drawing up the material.
The rationale is operational, not ceremonial. Development creates ownership of the message. Certification requires an independent assessment of the message in final form. Combining the roles removes a control designed to identify residual variance.
The development role can involve copywriting, medical strategy, content architecture, design direction, or coordination of agency output. The company should define the role by function rather than job title. A person may hold a medical qualification and still be ineligible to certify a material if that person was responsible for drawing it up.
A robust assignment process records:
- the individual who prepared or directed the material;
- the individual who performed medical review;
- the individual who completed legal and regulatory review;
- the eligible signatory;
- the date of certification;
- the asset version;
- the release owner.
This record prevents a common failure: assuming that a medical reviewer and a medical signatory are always the same role. They may be the same person in some workflows, provided the independence requirement is satisfied. They may not be treated as interchangeable by default.
Independence is defeated by late-stage substitution
A signatory can review an apparently complete asset while production staff retain authority to change it. That arrangement is incompatible with final-form control. The problem is not limited to deliberate amendment. Automated publishing, translation replacement, responsive design, and content-management permissions can all produce a post-certification variance.
Mitigation requires technical and procedural controls:
- lock the approved version before release;
- restrict editing permissions after certification;
- require a documented change request for any amendment;
- route material changes back through medical, legal, and regulatory review;
- create a new version when the content, destination, or presentation changes materially;
- retain the prior certified version rather than overwriting it.
A change does not need to alter the central claim to be relevant. A modified qualifier, changed reference, removed safety statement, or different audience setting can affect the compliance profile.
The highest-risk amendment is often the one treated as production housekeeping.
Record retention and audit readiness
ABPI rules require companies to preserve paper or electronic copies of certificates and the final form of certified promotional materials. For digital assets, this is a minimum record requirement, not a complete audit strategy.
A certificate without the final material is incomplete. The final material without the certificate does not establish certification. A screenshot without version identity may not establish which asset was issued. A review-platform entry without deployment evidence may show approval but not release.
The record set should connect four objects:
1. The material. The complete promotional asset, including relevant interactive and linked components.
2. The certificate. The identity and qualification of the certifier, with the certification date.
3. The review history. Medical, legal, and regulatory assessments, including resolved comments and approved references.
4. The release evidence. The version issued, channel used, audience configuration, and publication state.
For a digital campaign, the material may need to be represented through several controlled files or captures. A webpage, mobile rendering, downloadable PDF, email module, and QR-code destination may not be reducible to one document. The record should reflect the actual architecture of the asset.
Version control is the central audit variable
The central audit question is version identity. If the company cannot distinguish the certified version from the live version, the record is deficient regardless of the quality of the original review.
Version control should address:
- content revisions;
- design revisions;
- translation revisions;
- URL or destination changes;
- product-information updates;
- platform migrations;
- audience or access changes;
- replacement of images, video, or audio;
- expiration and withdrawal;
- reactivation of archived content.
A controlled system can generate version identifiers automatically. It cannot determine whether a change is material unless the process defines the threshold. That determination requires functional ownership from Medical, Legal, and Regulatory stakeholders.
A useful internal rule is to reopen review when a change can affect the interpretation, balance, required information, target audience, or route to approved content. Minor technical corrections may follow a separate process only if the company has defined and documented that process. No universal checklist applies to every organisation. Internal standard operating procedures vary. The control logic remains stable.
Audit readiness is tested by reconstruction
An audit-ready file should allow reconstruction without dependence on the memory of the campaign team. The reviewer should be able to trace:
- the initial brief;
- the evidence supporting each material claim;
- the review comments;
- the final approved version;
- the certificate;
- the deployment record;
- subsequent amendments;
- withdrawal or expiry actions.
This is particularly important when an agency, platform provider, or affiliate performs part of the process. Ownership must remain visible across organisational boundaries.
If a company can produce only a certificate and a generic PDF, it has preserved an approval artifact. It has not necessarily preserved the issued digital promotion.
A control sequence for practical implementation
The question of how to check medical signatory review of digital promotional materials is best answered through a sequence rather than a single form. The sequence should test both regulatory status and operational integrity.
1. Define the communication
The asset should be classified by market, audience, channel, product, indication, and promotional purpose. A professional website module, a public social-media asset, and a field-force email may contain related claims but do not present the same distribution context.
Ambiguity at this stage creates downstream variance. The review record should identify the intended recipients and the exact channel of issue.
2. Map the content boundary
The review team should enumerate every component that can affect the communication. This includes links, downloads, QR codes, embedded media, interactive modules, and conditional content. The boundary should be documented before certification.
Content that is outside the boundary should not be silently available through the asset. If it is necessary to the communication, it should be brought into the review.
3. Confirm claim and information support
Each clinical, comparative, safety, or outcome claim should be matched to the approved evidence and applicable product information. The assessment should include qualifiers and the visual or verbal prominence of mandatory information.
A technically accurate claim can still create a compliance problem if the surrounding presentation produces a misleading impression. Medical review is not a vocabulary check. It is an assessment of the communication as received by the intended audience.
4. Verify the final digital build
The reviewer should assess the rendered asset in the channel in which it will be issued. Desktop and mobile presentation may differ. Expandable sections may conceal information. Animation may change emphasis. A PDF conversion may alter pagination or truncate text.
The final form is the operational object. The source file is not.
5. Test every access pathway
Links and QR codes should be tested from the issued environment. The test should establish that the destination resolves to the intended content and that the content remains within the approved scope.
A successful technical response is not sufficient. The destination must also be clinically and regulatorily aligned.
6. Confirm the certifier and separation of duties
The certifier’s eligibility should be recorded. The development role should be distinct. The certificate should identify the exact asset and version, not merely the campaign name.
7. Lock, release, and monitor
After certification, the company should control publication permissions. The issued version should be captured. Monitoring should detect unauthorised amendment, broken pathways, changed destinations, and expiry of supporting content.
Monitoring is not a substitute for certification. It is mitigation against post-certification variance.
The definitive risk assessment
Medical signatory review of digital promotional materials is a final-form control. It is not a general endorsement of a campaign, a scientific opinion detached from the issued asset, or a one-time approval of a content concept.
Under the ABPI framework, Clause 8.1 places the certification requirement on the final form. The 2024 QR-code provision under Clause 12 provides an additional delivery route for prescribing information. It does not reduce the need to control the route, destination, and retained evidence. In the United States, MLR review provides a different committee structure and must not be presented as an equivalent legal mechanism.
The dominant risk is version variance. It occurs when the certified material, the deployed material, and the retained record no longer describe the same communication. The mitigation is controlled final-form review, separation of duties, restricted post-certification editing, tested digital pathways, and complete retention of the certificate and issued asset.
A company that controls those variables can demonstrate compliance with evidence. A company that controls only the approval meeting has controlled the discussion, not the promotion.